Fig. 7.

Mutant p53-specific silencing retards tumor growth in vivo. a, b. RD, PLC-PRF5, and H1975 cell lines were transduced with scrambled or the indicated mutant-p53-specific shRNAs and were collected 3 days later, and cells [RD (4 × 10⁶), PLC-PRF5 (3 × 10⁶) and H1975 (5 × 10⁶)] as a mixture of 75 μl cells in PBS and 75 μl Matrigel were injected into the flanks of SCID mice, and tumor growth was monitored regularly. Sizes of tumors are indicated in the graphs (a). Tumors harvested at end point in each case were used for H&E or anti-p53 staining on RD tumors (b). Values represent mean + SD. n = 4 (per group for RD and H1975 cells) and n = 5 (for PLC cells). *** indicates p value of <0.001. c, d Patient-derived triple-negative breast cancer xenografts were generated with 3–5 × 10⁶ cells as a mixture of 50 μl cells in PBS and 50 μl Matrigel and injected orthotopically into 8-week-old C.B-17 SCID mice (n = 5 mice per group). Mice were treated with siRNA admixed with liposomes (5 µg/mice), by tail vein injection, twice per week, and monitored regularly (c). Tumors harvested at end point in each case were used for anti-p53 staining (d). Representative images are shown. Quantitation of p53 staining is shown below. Values represent mean + SD. ** indicates p value of <0.01; *** indicates p value of <0.001